345
Participants
Start Date
August 27, 2013
Primary Completion Date
July 25, 2019
Study Completion Date
October 31, 2023
Enasidenib
Enasidenib tablets administered orally every day of 28-day treatment cycles until disease progression or unacceptable toxicities.
Cornell University Weill Medical College, New York
Memorial Sloan-Kettering Cancer Center - NYC, New York
Local Institution - 205, Toulouse
Local Institution - 202, Bordeaux
University of Miami Sylvester Cancer Center, Miami
Local Institution - 203, Pessac
Moffitt Cancer Center, Tampa
Florida Cancer Specialists, Sarasota
Sarah Cannon Research Institute Drug Development Unit, Nashville
Ohio State University, Gahanna
Cleveland Clinic, Cleveland
Mayo Clinic, Rochester
Washington University, St Louis
Local Institution - 204, Paris
MD Anderson Cancer Center, Houston
University Of Colorado Cancer Center, Aurora
Stanford Cancer Center, Stanford
Local Institution - 201, Villejuif
Oregon Health and Science University OHSU, Portland
City Of Hope, Duarte
Northwestern University, Chicago
Massachusetts General Hospital, Boston
Dana-Farber/Mass General Brigham Cancer Care, Inc, Boston
Ut Southwestern Medical Center At Dallas, Dallas
Lead Sponsor
Collaborators (1)
Agios Pharmaceuticals, Inc.
INDUSTRY
Celgene
INDUSTRY